New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics
Updates from the CLL14 and CLL2-GiVe trials on CLL
Highlights of ASH in CLL
John Gribben et al.
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Lenalidomide and ibrutinib: do they have a future in treating CLL?